Risk Factors for Conversion From Partial to Radical Nephrectomy ID’d
Identifying which patients are at increased risk of conversion is important for shared decision making.
Kidney Cancer
KIDNEY CANCER
Cytoreductive Nephrectomy Added to ICI Therapy Ups Survival in mRCC
Use of cytoreductive nephrectomy with an immune checkpoint inhibitor reduced death risk by 67%.
Scoring System Differentiates Malignant and Benign Renal Masses
A validated algorithm for assessing solid renal masses could be useful in clinical practice.
How Patients Choose Small Renal Mass Treatment Characterized
Patients choosing active surveillance perceived cancer and metastasis risks to be lower compared with those opting for surgery and ablation, a study showed.
Progression Criteria Could Improve Active Surveillance for Renal Masses
Recent findings may be useful for patient counseling and in designing active surveillance research studies.
Biomarker Could Improve Management of Renal Medullary Carcinoma
Study showed that 82% of patients had elevated CA-125 levels at any point during their disease course.
Post-RCC Treatment ESKD Risk Factors Identified
A study of patients treated for RCC found that radical nephrectomy, male sex, diabetes, hypertension, and chronic kidney disease are risk factors for end-stage kidney disease, according to investigators.
Exercise, Physical Activity Beneficial in Kidney Cancer Cases
In a study of patients who had ever been diagnosed with kidney cancer, those who reported exercise or physical activity in the past 30 days had reduced likelihood of reporting worse physical and mental health.
Proteinuria, AKI With New Tyrosine Kinase Inhibitors Characterized
Since FDA approval of imtainib, 40 newer tyrosine kinase inhibitor agents have been approved.
Bevacizumab Biosimilar Vegzelma Gets FDA Approval
Vegzelma is a vascular endothelial growth factor inhibitor.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Kidney Cancer
Loading... 
Loading...